# Boehringer Ingelheim

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/boehringer-ingelheim-2/

## Facts

| Field | Value |
| --- | --- |
| Country | DE |
| Description | German pharmaceutical company |
| OpenAlex ID | https://openalex.org/F4320310441 |
| ROR ID | https://ror.org/00q32j219 |
| Works | 4,003 |

## Funder papers

- [Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists](https://scholariq.org/papers/dapagliflozin-in-hfref-patients-treated-with-mineralocorticoid-receptor/)
- [KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)](https://scholariq.org/papers/kdigo-2025-clinical-practice-guideline-for-the-management-of-immunoglobulin-a/)
- [Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial](https://scholariq.org/papers/effects-of-empagliflozin-on-progression-of-chronic-kidney-disease-a-prespecified/)
- [Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors](https://scholariq.org/papers/genome-wide-profiling-of-non-smoking-related-lung-cancer-cells-reveals-common/)
- [High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome](https://scholariq.org/papers/high-prevalence-of-somatic-oncogenic-driver-alterations-in-patients-with-nsclc/)
- [Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery](https://scholariq.org/papers/levosimendan-in-patients-with-reduced-left-ventricular-function-undergoing/)
- [Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in <scp>EMPEROR‐Reduced</scp>](https://scholariq.org/papers/early-changes-in-estimated-glomerular-filtration-rate-post-initiation-of/)
- [A FIDELITY Analysis on Finerenone With SGLT-2i and GLP-1RA in CKD](https://scholariq.org/papers/a-fidelity-analysis-on-finerenone-with-sglt-2i-and-glp-1ra-in-ckd/)
- [Secondary analysis of the EMPACT-MI trial reveals cardiovascular–kidney efficacy and safety of empagliflozin after acute myocardial infarction](https://scholariq.org/papers/secondary-analysis-of-the-empact-mi-trial-reveals-cardiovascular-kidney-efficacy/)
- [Empagliflozin Reduces Risk of Hospitalization in Patients With Chronic Kidney Disease in the EMPA-KIDNEY Trial](https://scholariq.org/papers/empagliflozin-reduces-risk-of-hospitalization-in-patients-with-chronic-kidney/)
- [Quantitative Analysis of Instrument Motion Paths in Cataract Surgery across a Resident’s Training](https://scholariq.org/papers/quantitative-analysis-of-instrument-motion-paths-in-cataract-surgery-across-a/)
- [Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial](https://scholariq.org/papers/effect-of-empagliflozin-on-urinary-albumin-excretion-and-hypoxic-biomarkers-in/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.